Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151702 | 0.96 | FAAH (0.40) | FAAHCNR1CNR2EPHX2MAPT | |
| SCHEMBL28875951 | 0.94 | MAPT (0.39) | FAAHCNR1CNR2EPHX2MAPT | |
| SCHEMBL28314576 | 0.94 | FAAH (0.39) | FAAHCNR1CNR2EPHX2MAPT | |
| Methane SCHEMBL15437870 | 0.94 | FAAH (0.39) | FAAHCNR1CNR2EPHX2MAPT | |
| Ethane SCHEMBL15437842 | 0.94 | FAAH (0.39) | FAAHCNR1CNR2EPHX2MAPT | |
| Hydrochloric Acid SCHEMBL10612981 | 0.94 | FAAH (0.39) | FAAHCNR1CNR2EPHX2MAPT | |
| SCHEMBL7027311 | 0.94 | FAAH (0.39) | FAAHCNR1CNR2EPHX2MAPT | |
| SCHEMBL155564 | 0.86 | FAAH (0.44) | FAAHCNR1CNR2EPHX2MAPT | |
| Butane SCHEMBL8404111 | 0.86 | FAAH (0.47) | FAAHCNR1CNR2EPHX2MAPT | |
| SCHEMBL241530 | 0.84 | FAAH (0.43) | FAAHCNR1CNR2EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605622-A | Aliphatic polyester with malonic acid structure and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-114605622-A | Aliphatic polyester with malonic acid structure and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-06-25 | — | — | US | disclosed |
| EP-2875022-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2874620-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144500-A2 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144584-A2 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014015246-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015247-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | FAAH 240/4885CNR1 108/4885CNR2 115/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | FAAH 240/4885CNR1 108/4885CNR2 115/4885 |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | FAAH 240/4885CNR1 108/4885CNR2 115/4885 |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | FAAH 913/4885CNR1 1052/4885CNR2 1482/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | FAAH 240/4885CNR1 108/4885CNR2 115/4885 |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | FAAH 363/4885CNR1 129/4885CNR2 270/4885 |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | FAAH 363/4885CNR1 129/4885CNR2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.